Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial

David R Gandara, Everett Vokes, Mark Green, Phillip Bonomi, Russell Devore, Robert Comis, David Carbone, Daniel Karp, Chandra Belani

Research output: Contribution to journalArticle

130 Scopus citations

Abstract

Purpose: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. Patients and Methods: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m2 intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59%) were defined as platinum-refractory based on response status to prior therapy. Results: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16%) of 80 of patients, with similar response rates in platinum-sensitive and platinum- refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25%. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77%) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14%), with no fatal infections. Severe fluid retention was rare (4% of patients). Conclusions: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalJournal of Clinical Oncology
Volume18
Issue number1
StatePublished - Jan 2000
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial'. Together they form a unique fingerprint.

  • Cite this

    Gandara, D. R., Vokes, E., Green, M., Bonomi, P., Devore, R., Comis, R., Carbone, D., Karp, D., & Belani, C. (2000). Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial. Journal of Clinical Oncology, 18(1), 131-135.